MedTrace Logo

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-06-27

Study results available
· View outcomes & findings →

Summary

The prospective pilot study will address the critical need for more precise characterizations of the acute visual effects of the drug psilocybin by measuring the impact of acute psilocybin intoxication on a perceptual task known as visual surround suppression, compared to an active placebo control.

Conditions

  • Perception Disturbance
  • Visual Suppression
  • Psychedelic Experiences

Interventions

DRUG

Psilocybin

25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)

DRUG

Niacin

100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)

Sponsors & Collaborators

Principal Investigators

  • Jessica Nielson, PhD · University of Minnesota

  • Link Swanson, PhD(c) · University of Minnesota

  • Sophie Jungers, BS · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2023-09-01
Completion
2023-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04424225 on ClinicalTrials.gov